Kaposi's sarcoma-associated herpesvirus ORF45 mediates transcriptional activation of the HIV-1 long terminal repeat via RSK2

Journal of Virology

Volumn 88, Issue 12, 2014, Pages 7024-7035

  Karijolich, John ^a   Zhao, Yang ^b   Peterson, Bret ^a   Zhou, Qiang ^b   Glaunsinger, Britt ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN ORF45; RNA POLYMERASE II; S6 KINASE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; HEK293 CELL LINE; HERPES VIRUS INFECTION; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

ANIMALS; CELL LINE; COINFECTION; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; IMMEDIATE-EARLY PROTEINS; MICE; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; TRANSCRIPTIONAL ACTIVATION;

EID: 84901340050     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00931-14     Document Type: Article

References (64)

1. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d'Agay M-F, Clauvel J-P, Raphael M, Degos L, Sigaux F. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86:1276-1280.
2. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332:1186-1191. http://dx.doi.org/10.1056/NEJM199505043321802.
3. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869. http://dx.doi.org/10.1126/science.7997879.
4. Ganem D. 2010. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J. Clin. Invest. 120:939-949. http://dx.doi.org/10.1172/JCI40567.
5. Aoki Y, Tosato G. 2004. HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. Blood 104:810-814. http://dx.doi.org/10.1182/blood-2003-07-2533.
6. Buonaguro L, Barillari G, Chang HK, Bohan CA, Kao V, Morgan R, Gallo RC, Ensoli B. 1992. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J. Virol. 66:7159-7167.
7. Barillari G, Sgadari C, Palladino C, Gendelman R, Caputo A, Morris CB, Nair BC, Markham P, Nel A, Stürzl M, Ensoli B. 1999. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. J. Immunol. 163:1929-1935.
8. Varthakavi V, Browning PJ, Spearman P. 1999. Human immunodeficiency virus replication in a primary effusion lymphoma cell line stimulates lytic-phase replication of Kaposi's sarcoma-associated herpesvirus. J. Virol. 73:10329-10338.
9. Merat R, Amara A, Lebbe C, de The H, Morel P, Saib A. 2002. HIV-1 infection of primary effusion lymphoma cell line triggers Kaposi's sarcoma-associated herpesvirus (KSHV) reactivation. Int. J. Cancer 97:791-795. http://dx.doi.org/10.1002/ijc.10086.
10. Harrington W, Jr, Sieczkowski L, Sosa C, Chan-a-Sue S, Cai JP, Cabral L, Wood C. 1997. Activation of HHV-8 by HIV-1 tat. Lancet 349:774-775. http://dx.doi.org/10.1016/S0140-6736(05)60199-7.
11. Suligoi B, Dorrucci M, Uccella I, Andreoni M, Rezza G, Italian Seroconversion S. 2003. Effect of multiple herpesvirus infections on the progression of HIV disease in a cohort of HIV seroconverters. J. Med. Virol. 69:182-187. http://dx.doi.org/10.1002/jmv.10281.
12. Chandra A, Demirhan I, Massambu C, Pyakurel P, Kaaya E, Enbom M, Urassa W, Linde A, Heiden T, Biberfeld P, Doerr HW, Cinatl J, Loewer J, Chandra P. 2003. Cross-talk between human herpesvirus 8 and the transactivator protein in the pathogenesis of Kaposi's sarcoma in HIVinfected patients. Anticancer Res. 23:723-728.
13. Caselli E, Galvan M, Cassai E, Caruso A, SighinolfiL, Di Luca D. 2005. Human herpesvirus 8 enhances human immunodeficiency virus replication in acutely infected cells and induces reactivation in latently infected cells. Blood 106:2790-2797. http://dx.doi.org/10.1182/blood-2005-04-1390.
14. Blasig C, Zietz C, Haar B, Neipel F, Esser S, Brockmeyer NH, Tschachler E, Colombini S, Ensoli B, Stürzl M. 1997. Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8. J. Virol. 71:7963-7968.
15. BoshoffC, Schulz TF, Kennedy MM, Graham AK, Fisher C, Thomas A, McGee JO, Weiss RA, O'Leary JJ. 1995. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat. Med. 1:1274-1278. http://dx.doi.org/10.1038/nm1295-1274.
16. Sharp TV, BoshoffC. 2000. Kaposi's sarcoma-associated herpesvirus: from cell biology to pathogenesis. IUBMB Life 49:97-104. http://dx.doi.org/10.1080/15216540050022395.
17. Mesri EA, Cesarman E, Arvanitakis L, Rafii S, Moore MA, Posnett DN, Knowles DM, Asch AS. 1996. Human herpesvirus-8/Kaposi's sarcomaassociated herpesvirus is a new transmissible virus that infects B cells. J. Exp. Med. 183:2385-2390. http://dx.doi.org/10.1084/jem.183.5.2385.
18. Myoung J, Ganem D. 2011. Infection of primary human tonsillar lymphoid cells by KSHV reveals frequent but abortive infection of T cells. Virology 413:1-11. http://dx.doi.org/10.1016/j.virol.2010.12.036.
19. Harrington WJ, Jr, Bagasra O, Sosa CE, Bobroski LE, Baum M, Wen XL, Cabral L, Byrne GE, Pomerantz RJ, Wood C. 1996. Human herpesvirus type 8 DNA sequences in cell-free plasma and mononuclear cells of Kaposi's sarcoma patients. J. Infect. Dis. 174:1101-1105. http://dx.doi.org/10.1093/infdis/174.5.1101.
20. + T cells. J. Infect. Dis. 176:541. (Letter.) http://dx.doi.org/10.1086/514072.
21. BoshoffC, Whitby D, Hatziioannou T, Fisher C, van der Walt J, Hatzakis A, Weiss R, Schulz T. 1995. Kaposi's-sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet 345:1043-1044. http://dx.doi.org/10.1016/S0140-6736(95)90780-7.
22. Sathish N, Wang X, Yuan Y. 2012. Tegument proteins of Kaposi's sarcoma-associated herpesvirus and related gamma-herpesviruses. Front. Microbiol. 3:98. http://dx.doi.org/10.3389/fmicb.2012.00098.
23. Bechtel JT, Winant RC, Ganem D. 2005. Host and viral proteins in the virion of Kaposi's sarcoma-associated herpesvirus. J. Virol. 79:4952-4964. http://dx.doi.org/10.1128/JVI.79.8.4952-4964.2005.
24. Zhu FX, Chong JM, Wu L, Yuan Y. 2005. Virion proteins of Kaposi's sarcoma-associated herpesvirus. J. Virol. 79:800-811. http://dx.doi.org/10.1128/JVI.79.2.800-811.2005.
25. Huang LM, Chao MF, Chen MY, Shih H, Chiang YP, Chuang CY, Lee CY. 2001. Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1. J. Biol. Chem. 276:13427-13432. http://dx.doi.org/10.1074/jbc. M011314200.
26. Hyun TS, Subramanian C, Cotter MA, II, Thomas RA, Robertson ES. 2001. Latency-associated nuclear antigen encoded by Kaposi's sarcomaassociated herpesvirus interacts with Tat and activates the long terminal repeat of human immunodeficiency virus type 1 in human cells. J. Virol. 75:8761-8771. http://dx.doi.org/10.1128/JVI.75.18.8761-8771.2001.
27. Caselli E, Menegazzi P, Bracci A, Galvan M, Cassai E, Di Luca D. 2001. Human herpesvirus-8 (Kaposi's sarcoma-associated herpesvirus) ORF50 interacts synergistically with the tat gene product in transactivating the human immunodeficiency virus type 1 LTR. J. Gen. Virol. 82:1965-1970. http://vir.sgmjournals.org/content/82/8/1965.long.
28. Kuang E, Tang Q, Maul GG, Zhu F. 2008. Activation of p90 ribosomal S6 kinase by ORF45 of Kaposi's sarcoma-associated herpesvirus and its role in viral lytic replication. J. Virol. 82:1838-1850. http://dx.doi.org/10.1128/JVI.02119-07.
29. Kuang E, Fu B, Liang Q, Myoung J, Zhu F. 2011. Phosphorylation of eukaryotic translation initiation factor 4B (EIF4B) by open reading frame 45/p90 ribosomal S6 kinase (ORF45/RSK) signaling axis facilitates protein translation during Kaposi sarcoma-associated herpesvirus (KSHV) lytic replication. J. Biol. Chem. 286:41171-41182. http://dx.doi.org/10.1074/jbc. M111.280982.
30. Myoung J, Ganem D. 2011. Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction. J. Virol. Methods 174:12-21. http://dx.doi.org/10.1016/j.jviromet.2011.03.012.
31. Stürzl M, Gaus D, Dirks WG, Ganem D, Jochmann R. 2013. Kaposi's sarcoma-derived cell line SLK is not of endothelial origin, but is a contaminant from a known renal carcinoma cell line. Int. J. Cancer 132:1954-1958. http://dx.doi.org/10.1002/ijc.27849.
32. Yang Z, Zhu Q, Luo K, Zhou Q. 2001. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature 414: 317-322. http://dx.doi.org/10.1038/35104575.
33. Li Z, Guo J, Wu Y, Zhou Q. 2013. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tattransactivation. Nucleic Acids Res. 41:277-287. http://dx.doi.org/10.1093/nar/gks976.
34. Kang H, Wiedmer A, Yuan Y, Robertson E, Lieberman PM. 2011. Coordination of KSHV latent and lytic gene control by CTCF-cohesin mediated chromosome conformation. PLoS Pathog. 7:e1002140. http://dx.doi.org/10.1371/journal.ppat.1002140.
35. Jäger S, Cimermancic P, Gulbahce N, Johnson JR, McGovern KE, Clarke SC, Shales M, Mercenne G, Pache L, Li K, Hernandez H, Jang GM, Roth SL, Akiva E, Marlett J, Stephens M, D'Orso I, Fernandes J, Fahey M, Mahon C, O'Donoghue AJ, Todorovic A, Morris JH, Maltby DA, Alber T, Cagney G, Bushman FD, Young JA, Chanda SK, Sundquist WI, Kortemme T, Hernandez RD, Craik CS, Burlingame A, Sali A, Frankel AD, Krogan NJ. 2012. Global landscape of HIV-human protein complexes. Nature 481:365-370. http://dx.doi.org/10.1038/nature10719.
36. Lin JX, Spolski R, Leonard WJ. 2008. Critical role for Rsk2 in T-lymphocyte activation. Blood 111:525-533. http://dx.doi.org/10.1182/blood-2007-02-072207.
37. Poteet-Smith CE, Smith JA, Lannigan DA, Freed TA, Sturgill TW. 1999. Generation of constitutively active p90 ribosomal S6 kinase in vivo. Implications for the mitogen-activated protein kinase-activated protein kinase family. J. Biol. Chem. 274:22135-22138.
38. Listerman I, Sapra AK, Neugebauer KM. 2006. Cotranscriptional coupling of splicing factor recruitment and precursor messenger RNA splicing in mammalian cells. Nat. Struct. Mol. Biol. 13:815-822. http://dx.doi.org/10.1038/nsmb1135.
39. Bechtel JT, Liang Y, Hvidding J, Ganem D. 2003. Host range of Kaposi's sarcoma-associated herpesvirus in cultured cells. J. Virol. 77:6474-6481. http://dx.doi.org/10.1128/JVI.77.11.6474-6481.2003.
40. Zhou Q, Yik JH. 2006. The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiol. Mol. Biol. Rev. 70:646-659. http://dx.doi.org/10.1128/MMBR.00011-06.
41. Aguilar-Cordova E, Chinen J, Donehower L, Lewis DE, Belmont JW. 1994. A sensitive reporter cell line for HIV-1 tat activity, HIV-1 inhibitors, and T cell activation effects. AIDS Res. Hum. Retroviruses 10:295-301. http://dx.doi.org/10.1089/aid.1994.10.295.
42. Zeniou M, Ding T, Trivier E, Hanauer A. 2002. Expression analysis of RSK gene family members: the RSK2 gene, mutated in Coffin-Lowry syndrome, is prominently expressed in brain structures essential for cognitive function and learning. Hum. Mol. Genet. 11:2929-2940. http://dx.doi.org/10.1093/hmg/11.23.2929.
43. Dümmler BA, Hauge C, Silber J, Yntema HG, Kruse LS, Kofoed B, Hemmings BA, Alessi DR, Frodin M. 2005. Functional characterization of human RSK4, a new 90-kDa ribosomal S6 kinase, reveals constitutive activation in most cell types. J. Biol. Chem. 280:13304-13314. http://dx.doi.org/10.1074/jbc. M408194200.
44. Hetzer C, Bisgrove D, Cohen MS, Pedal A, Kaehlcke K, Speyerer A, Bartscherer K, Taunton J, Ott M. 2007. Recruitment and activation of RSK2 by HIV-1 Tat. PLoS One 2:e151. http://dx.doi.org/10.1371/journal.pone.0000151.
45. Zhu FX, Cusano T, Yuan Y. 1999. Identification of the immediate-early transcripts of Kaposi's sarcoma-associated herpesvirus. J. Virol. 73:5556-5567.
46. Jia Q, Chernishof V, Bortz E, McHardy I, Wu TT, Liao HI, Sun R. 2005. Murine gammaherpesvirus 68 open reading frame 45 plays an essential role during the immediate-early phase of viral replication. J. Virol. 79: 5129-5141. http://dx.doi.org/10.1128/JVI.79.8.5129-5141.2005.
47. Kang S, Dong S, Gu TL, Guo A, Cohen MS, Lonial S, Khoury HJ, Fabbro D, Gilliland DG, Bergsagel PL, Taunton J, Polakiewicz RD, Chen J. 2007. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 12:201-214. http://dx.doi.org/10.1016/j.ccr.2007.08.003.
48. Bignone PA, Lee KY, Liu Y, Emilion G, Finch J, Soosay AE, Charnock FM, Beck S, Dunham I, Mungall AJ, Ganesan TS. 2007. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene 26:683-700. http://dx.doi.org/10.1038/sj.onc.1209827.
49. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, Nijkamp W, Weigelt B, Agami R, Ge W, Cavet G, Linsley PS, Beijersbergen RL, Bernards R. 2004.Alarge-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428:431-437. http://dx.doi.org/10.1038/nature02371.
50. Thakur A, Rahman KW, Wu J, Bollig A, Biliran H, Lin X, Nassar H, Grignon DJ, Sarkar FH, Liao JD. 2007. Aberrant expression of X-linked genes RbAp46, Rsk4, and Cldn2 in breast cancer. Mol. Cancer Res. 5:171-181. http://dx.doi.org/10.1158/1541-7786.MCR-06-0071.
51. Trivier E, De Cesare D, Jacquot S, Pannetier S, Zackai E, Young I, Mandel JL, Sassone-Corsi P, Hanauer A. 1996. Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome. Nature 384:567-570. http://dx.doi.org/10.1038/384567a0.
52. Jacquot S, Merienne K, De Cesare D, Pannetier S, Mandel JL, Sassone-Corsi P, Hanauer A. 1998. Mutation analysis of the RSK2 gene in Coffin-Lowry patients: extensive allelic heterogeneity and a high rate of de novo mutations. Am. J. Hum. Genet. 63:1631-1640. http://dx.doi.org/10.1086/302153.
53. Hanauer A, Young ID. 2002. Coffin-Lowry syndrome: clinical and molecular features. J. Med. Genet. 39:705-713. http://dx.doi.org/10.1136/jmg.39.10.705.
54. Anjum R, Blenis J. 2008. The RSK family of kinases: emerging roles in cellular signalling. Nat. Rev. Mol. Cell Biol. 9:747-758. http://dx.doi.org/10.1038/nrm2509.
55. Kuang E, Wu F, Zhu F. 2009. Mechanism of sustained activation of ribosomal S6 kinase (RSK) and ERK by Kaposi sarcoma-associated herpesvirus ORF45: multiprotein complexes retain active phosphorylated ERK and RSK and protect them from dephosphorylation. J. Biol. Chem. 284:13958-13968. http://dx.doi.org/10.1074/jbc. M900025200.
56. Morrison DK, Davis RJ. 2003. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu. Rev. Cell Dev. Biol. 19:91-118. http://dx.doi.org/10.1146/annurev.cellbio.19.111401.091942.
57. Godden-Kent D, Talbot SJ, BoshoffC, Chang Y, Moore P, Weiss RA, Mittnacht S. 1997. The cyclin encoded by Kaposi's sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J. Virol. 71:4193-4198.
58. Kaldis P. 2005. The N-terminal peptide of the Kaposi's sarcomaassociated herpesvirus (KSHV)-cyclin determines substrate specificity. J. Biol. Chem.280:11165-11174.http://dx.doi.org/10.1074/jbc. M40888 7200.
59. Li M, Lee H, Yoon DW, Albrecht JC, Fleckenstein B, Neipel F, Jung JU. 1997. Kaposi's sarcoma-associated herpesvirus encodes a functional cyclin. J. Virol. 71:1984-1991.
60. Holz MK, Ballif BA, Gygi SP, Blenis J. 2005. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123:569-580. http://dx.doi.org/10.1016/j.cell.2005.10.024.
61. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-485. http://dx.doi.org/10.1038/nature11286.
62. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. 2005. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366:549-555. http://dx.doi.org/10.1016/S0140-6736(05)67098-5.
63. Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, Bradner J, Sebastiani P, Margolis DM, Montano M. 2012. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J. Leukoc. Biol. 92:1147-1154. http://dx.doi.org/10.1189/jlb.0312165.
64. Deeks SG. 2012. HIV: shock and kill. Nature 487:439-440. http://dx.doi.org/10.1038/487439a.